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Cochrane Corner
Section Editor: Graeme J. Hankey, MD, FRCP
Interventions for Deliberately Altering Blood Pressure
in Acute Stroke
Chamila M. Geeganage, MB, BS, MSc; Philip M.W. Bath, MD, FRCP
High blood pressure (BP) is common in both acuteischemic stroke and primary intracerebral hemorrhage.
Both high and low BP are associated with a poor outcome.
Hence, drugs that elevate a low BP or reduce a high BP might
be beneficial. We systematically assessed the effect of delib-
erate BP-altering in patients with acute stroke.1
Search Strategy
We searched the Cochrane Stroke Group Trials Register,
the Cochrane Database of Systematic Reviews, Cochrane
Central Register of Controlled Trials, MEDLINE, EMBASE
and other databases, reference lists of relevant publications, and
contacted researchers in the field. All randomized, controlled
trials that aimed to alter BP in acute ischemic stroke or acute
primary intracerebral hemorrhage were included; treatment
had to be initiated within 1 week of stroke onset. Uncon-
trolled studies, controlled studies involving only active com-
parators, and studies of patients with subarachnoid hemor-
rhage were excluded.
Data on early and late case fatality, early neurological
deterioration, late disability/dependency, stroke recur-
rence, quality of life, discharge site, hospital costs, base-
line and on-treatment BP, and heart rate were sought,
ideally by intention to treat. Methodological quality of the
trials, especially relating to concealment of allocation, was
also assessed. Data were analyzed using RevMan 5; OR
with random-effects model for binary data and weighted
mean difference for continuous data each with 95% CIs,
were calculated.
Main Results
Twelve trials involving 1153 participants (range, 15 to 404) were
included (603 active, 550 placebo/control). The trials mostly
tested drugs that lower BP: angiotensin-converting enzyme
inhibitors, angiotensin receptor antagonists (ARA), calcium
channel blockers, clonidine, glyceryl trinitrate/nitroglycerine,
thiazide diuretics, and mixed antihypertensive therapy. One trial
tested phenylephrine (sympathomimetic).2 At 24 hours after
randomization (Figure), the antihypertensive agents lowered BP:
angiotensin-converting enzyme inhibitors weighted mean differ-
ence 6/5 mm Hg (95% CI, 22 to 10/18 to 7), ARA
3/3 mm Hg (95% CI, 7 to 2/6 to 0.4), intravenous
calcium channel blockers 32/13 mm Hg (95% CI, 65 to
1/31 to 6), oral calcium channel blockers 13/6 mm Hg
(95% CI,43 to 17/14 to 2), glyceryl trinitrate/nitroglycerine
10/1 mm Hg (95% CI, 18 to 3/5 to 3), and mixed
antihypertensives 11 mm Hg (95% CI, 14 to 8). Phenyl-
ephrine nonsignificantly increased BP by 21/1 mm Hg (95% CI,
13 to 55/15 to 16). Functional outcome (OR, 1; 95% CI, 0.8
to 1.5) and death (OR, 0.7; 95% CI, 0.4 to 1) were not altered by
any of the drugs; data on the other outcomes were not available.
Discussion
Twelve small trials, involving 1153 participants with either
ischemic stroke or primary intracerebral hemorrhage, of
deliberate BP alteration in acute stroke have been reported to
date. Of the vasoactive drugs studied, angiotensin-converting
enzyme inhibitors, ARA, calcium channel blockers, glyceryl
trinitrate/nitroglycerine, and combined antihypertensive ther-
apy lowered BP over the first 24 to 48 hours of treatment.
Phenylephrine tended to increased BP at 24 hours. Insuffi-
cient data were present to assess the effect of changing BP on
functional outcome. However, several large trials are assess-
ing whether blood pressure should be lowered or not, includ-
ing with an ARA (Scandinavian Candesartan Acute Stroke
Trial), glyceryl trinitrate/nitroglycerine (Efficacy of Nitric
Oxide in Stroke) or “usual therapy” (Intensive Blood Pressure
Reduction in Acute Cerebral Haemorrhage Trial 2).3–5
Conclusion
There is insufficient evidence to evaluate the effect of altering
BP on outcome during the acute phase of stroke. In patients
with acute stroke, calcium channel blockers, angiotensin-
converting enzyme inhibitors, ARA, and glyceryl trinitrate/
nitroglycerine each lower BP, whereas phenylephrine has
vasopressor properties.
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Implications for Practice and Future Research
The data from the trials included in this review are too
limited to provide reliable guidance on whether it is safe
and effective to actively lower or raise BP in patients with
acute stroke or, indeed, the precise effects this will have on
BP. Large randomized, controlled trials of BP management
addressing issues such as whether BP be elevated or
lowered, the type of treatment, time of treatment initiation,
treatment duration, and whether prestroke antihypertensive
therapy be continued or stopped during the acute phase of
stroke, are required. Several large trials addressing these
issues are currently ongoing.
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Figure. Forest plot showing the effect of different BP-lowering drugs on systolic BP at 24 hours.
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